Announcements Trials
Browse Landscape

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 13132Triple Negative Breast Neoplasms 1149Neoplasms 749Ovarian Neoplasms 680Neoplasm Metastasis 590Lung Neoplasms 582Colorectal Neoplasms 580Prostatic Neoplasms 560Carcinoma, Non-Small-Cell Lung 535Pancreatic Neoplasms 380Melanoma 366Stomach Neoplasms 350Colonic Neoplasms 330Motor Activity 285Breast Neoplasms, Male 285Carcinoma, Intraductal, Noninfiltrating 277Uterine Cervical Neoplasms 267Head and Neck Neoplasms 266Endometrial Neoplasms 256Carcinoma, Renal Cell 216Sarcoma 203Urinary Bladder Neoplasms 192Squamous Cell Carcinoma of Head and Neck 192Lymphedema 190Esophageal Neoplasms 189Breast Carcinoma In Situ 189Brain Neoplasms 183Fatigue 166Carcinoma, Ovarian Epithelial 151Small Cell Lung Carcinoma 148

Interventions

trastuzumab deruxtecan 1Isovaleryl-CoA Dehydrogenase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2 Overexpression × Breast × Clear all
NCT07035353 2025-06-25

A Real-world Clinical Study of T-DXd for the Treatment of Chinese Patients With HER2 Overexpressing and HER2 Underexpressing Advanced Breast Cancer

Tianjin Medical University Cancer Institute and Hospital

Not yet recruiting
200 enrolled
Breast

HER2 Overexpression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡